Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2018

Open Access 01-12-2018 | Study protocol

Mesenchymal stem cells in the treatment of Cesarean section skin scars: study protocol for a randomized, controlled trial

Authors: Dazhi Fan, Qing Xia, Shuzhen Wu, Shaoxin Ye, Li Liu, Wen Wang, Xiaoling Guo, Zhengping Liu

Published in: Trials | Issue 1/2018

Login to get access

Abstract

Background

Cesarean delivery has already become a very common method of delivery around the world, especially in low-income countries. Hypertrophic scars and wound infections have affected younger mothers and frustrated obstetricians for a long time. Mesenchymal stem cells (MSCs) have strong potential for self-renewal and differentiation to multilineage cells. Previous studies have demonstrated that MSCs are involved in enhancing diabetic wound healing. Therefore, this study is designed to investigate the safety and efficacy of using MSCs in the treatment of Cesarean section skin scars.

Methods

This trial is a prospective, randomized, double-blind, placebo-controlled, single-center trial with three parallel groups. Ninety eligible participants will be randomly allocated to placebo, low-dose (transdermal hydrogel MSCs; 3 × 106 cells) or high-dose (transdermal hydrogel MSCs; 6 × 106 cells) groups at a 1:1:1 allocation ratio according to a randomization list, once a day for six consecutive days. Study duration will last for 6 months, comprising a 1 week run-in period and 24 weeks of follow-up. The primary aim of this trial is to compare the difference in Vancouver Scar Scale rating among the three groups at the 6th month. Adverse events, including severe and slight signs or symptoms, will be documented in case report forms. The study will be conducted at the Department of Obstetric of Southern Medical University Affiliated Maternal & Child Health Hospital of Foshan.

Discussion

This trial is the first investigation of the potential for therapeutic use of MSCs for the management of women’s skin scar after Cesarean delivery. The results will give us an effective therapeutic strategy to combat Cesarean section skin scars, even with uterine scarring.

Trial registration

ClinicalTrials.gov, NCT02772289. Registered on 10 May 2016.
Appendix
Available only for authorised users
Literature
1.
Lumbiganon P, Laopaiboon M, Gulmezoglu AM, Souza JP, Taneepanichskul S, Ruyan P, et al. Method of delivery and pregnancy outcomes in Asia: The WHO global survey on maternal and perinatal health 2007–08. Lancet. 2010;375:490–9.CrossRefPubMed
2.
Li HT, Luo S, Trasande L, Hellerstein S, Kang C, Li JX, et al. Geographic variations and temporal trends in Cesarean delivery rates in China, 2008–2014. JAMA. 2017;317:69–76.CrossRefPubMed
3.
Stapleton H, Team DT. Wound healing in obese women following Caesarean section. Aust Nurs Midwifery J. 2015;23:34.PubMed
4.
Owens SM, Brozanski BS, Meyn LA, Wiesenfeld HC. Antimicrobial prophylaxis for Cesarean delivery before skin incision. Obstet Gynecol. 2009;114:573–9.CrossRefPubMed
5.
Sun BK, Siprashvili Z, Khavari PA. Advances in skin grafting and treatment of cutaneous wounds. Science. 2014;346:941–5.CrossRefPubMed
6.
Fu X, Li H. Mesenchymal stem cells and skin wound repair and regeneration: Possibilities and questions. Cell Tissue Res. 2009;335:317–21.CrossRefPubMed
7.
Khanna S, Biswas S, Shang Y, Collard E, Azad A, Kauh C, et al. Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PLoS One. 2010;5:e9539.CrossRefPubMedPubMedCentral
8.
Xu F, Zhang C, Graves DT. Abnormal cell responses and role of TNF-α in impaired diabetic wound healing. Biomed Res Int. 2013;2013:754802.PubMedPubMedCentral
9.
Siqueira MF, Li J, Chehab L, Desta T, Chino T, Krothpali N, et al. Impaired wound healing in mouse models of diabetes is mediated by TNF-α dysregulation and associated with enhanced activation of forkhead box O1 (FOXO1). Diabetologia. 2010;53:378–88.CrossRefPubMed
10.
Han YP, Tuan TL, Wu H, Hughes M, Garner WL. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. J Cell Sci. 2001;114:131–9.PubMedPubMedCentral
11.
Yang QQ, Yang SS, Tan JL, Luo GX, He WF, Wu J. Process of hypertrophic scar formation: Expression of eukaryotic initiation factor 6. Chin Med J (Engl). 2015;128:2787–91.CrossRef
12.
Xue M, Jackson CJ. Extracellular matrix reorganization during wound healing and its impact on abnormal scarring. Adv Wound Care (New Rochelle). 2015;4:119–36.CrossRef
13.
Ray S, Ju X, Sun H, Finnerty CC, Herndon DN, Brasier AR. The IL-6 trans-signaling-STAT3 pathway mediates ECM and cellular proliferation in fibroblasts from hypertrophic scar. J Invest Dermatol. 2013;133:1212–20.CrossRefPubMedPubMedCentral
14.
15.
Withycombe C, Purdy KJ, Maddocks SE. Micro-management: Curbing chronic wound infection. Mol Oral Microbiol. 2017;32:263–74.CrossRefPubMed
16.
Connery SA, Downes KL, Young C. A retrospective study evaluating silver-impregnated dressings on Cesarean wound healing. Adv Skin Wound Care. 2012;25:414–9.CrossRefPubMed
17.
Zuarez-Easton S, Zafran N, Garmi G, Salim R. Postcesarean wound infection: Prevalence, impact, prevention, and management challenges. Int J Womens Health. 2017;9:81–8.CrossRefPubMedPubMedCentral
18.
Fitzwater JL, Tita AT. Prevention and management of Cesarean wound infection. Obstet Gynecol Clin North Am. 2014;41:671–89.CrossRefPubMed
19.
Samadi S, Khadivzadeh T, Emami A, Moosavi NS, Tafaghodi M, Behnam HR. The effect of Hypericum perforatum on the wound healing and scar of Cesarean. J Altern Complement Med. 2010;16:113–7.CrossRefPubMed
20.
Chen X, Yang X, Wu R, Chen W, Xie H, Qian X, et al. Therapeutic effects of Wharton jelly-derived mesenchymal stem cells on rat abortion models. J Obstet Gynaecol Res. 2016;42(8):972–82.CrossRefPubMed
21.
Fan L, Hu C, Chen J, Cen P, Wang J, Li L. Interaction between mesenchymal stem cells and B-cells. Int J Mol Sci. 2016;17(5):650.CrossRefPubMedCentral
22.
Hu J, Li H, Chi G, Yang Z, Zhao Y, Liu W, et al. IL-1RA gene-transfected bone marrow-derived mesenchymal stem cells in APA microcapsules could alleviate rheumatoid arthritis. Int J Clin Exp Med. 2015;8:706–13.PubMedPubMedCentral
23.
Glenn JD, Smith MD, Calabresi PA, Whartenby KA. Mesenchymal stem cells differentially modulate effector CD8+ T cell subsets and exacerbate experimental autoimmune encephalomyelitis. Stem Cells. 2014;32:2744–55.CrossRefPubMed
24.
Yoshioka M, Tanimoto K, Tanne Y, Sumi K, Awada T, Oki N, et al. Bone regeneration in artificial jaw cleft by use of carbonated hydroxyapatite particles and mesenchymal stem cells derived from iliac bone. Int J Dent. 2012;2012:352510.CrossRefPubMedPubMedCentral
25.
Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial. JAMA. 2012;308:2369–79.CrossRefPubMedPubMedCentral
26.
Domergue S, Bony C, Maumus M, Toupet K, Frouin E, Rigau V, et al. Comparison between stromal vascular fraction and adipose mesenchymal stem cells in remodeling hypertrophic scars. PLoS One. 2016;11:e0156161.CrossRefPubMedPubMedCentral
27.
Liu S, Jiang L, Li H, Shi H, Luo H, Zhang Y, et al. Mesenchymal stem cells prevent hypertrophic scar formation via inflammatory regulation when undergoing apoptosis. J Invest Dermatol. 2014;134:2648–57.CrossRefPubMed
28.
Gu C, Huang S, Gao D, Wu Y, Li J, Ma K, et al. Angiogenic effect of mesenchymal stem cells as a therapeutic target for enhancing diabetic wound healing. Int J Low Extrem Wounds. 2014;13:88–93.CrossRefPubMed
29.
Isakson M, de Blacam C, Whelan D, McArdle A, Clover AJ. Mesenchymal stem cells and cutaneous wound healing: Current evidence and future potential. Stem Cells Int. 2015;2015:831095.CrossRefPubMedPubMedCentral
30.
Falanga V, Iwamoto S, Chartier M, Yufit T, Butmarc J, Kouttab N, et al. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng. 2007;13:1299–312.CrossRefPubMed
31.
Badiavas EV, Falanga V. Treatment of chronic wounds with bone marrow-derived cells. Arch Dermatol. 2003;139:510–6.CrossRefPubMed
32.
Yoshikawa T, Mitsuno H, Nonaka I, Sen Y, Kawanishi K, Inada Y, et al. Wound therapy by marrow mesenchymal cell transplantation. Plast Reconstr Surg. 2008;121:860–77.CrossRefPubMed
33.
Dash NR, Dash SN, Routray P, Mohapatra S, Mohapatra PC. Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. Rejuvenation Res. 2009;12:359–66.CrossRefPubMed
34.
Hou J, Ndasauka Y, Jiang Y, Ye Z, Wang Y, Yang L, et al. Excessive use of WeChat, social interaction and locus of control among college students in China. PLoS One. 2017;12:e0183633.CrossRefPubMedPubMedCentral
35.
Liang J, Zhang H, Hua B, Wang H, Wang J, Han Z, et al. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult Scler. 2009;15:644–6.CrossRefPubMed
36.
37.
38.
Lu SB, Wu ZZ, Fu XB, Guo QY, Cheng J, Zhao SC, et al. Strategic research on the industrial development of innovative technology in cell technology-related regenerative medicine in China. Eng Sci. 2017;19:95–9.CrossRef
39.
Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica. 2006;91:1017–26.PubMed
40.
Li X, Li J, Ju X, Chen X, Wu X. Abdominal scar characteristics as a predictor of cervical stenosis after abdominal radical trachelectomy. Oncotarget. 2016;7(25):37755–61.PubMedPubMedCentral
41.
Liu HB, Tang D, Cao HY, Li KC. Reliability of Vancouver Scar Scale. Chin J Rehabili Med. 2006;21:240–2.
42.
43.
Zhao Q, Ren H, Li X, Chen Z, Zhang X, Gong W, et al. Differentiation of human umbilical cord mesenchymal stromal cells into low immunogenic hepatocyte-like cells. Cytotherapy. 2009;11:414–26.CrossRefPubMed
44.
Zahorec P, Koller J, Danisovic L, Bohac M. Mesenchymal stem cells for chronic wounds therapy. Cell Tissue Bank. 2015;16:19–26.CrossRefPubMed
45.
Lu D, Chen B, Liang Z, Deng W, Jiang Y, Li S, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: A double-blind, randomized, controlled trial. Diabetes Res Clin Pract. 2011;92:26–36.CrossRefPubMed
46.
Prochazka V, Gumulec J, Jaluvka F, Salounova D, Jonszta T, Czerny D, et al. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplant. 2010;19:1413–24.CrossRefPubMedPubMedCentral
47.
Metadata
Title
Mesenchymal stem cells in the treatment of Cesarean section skin scars: study protocol for a randomized, controlled trial
Authors
Dazhi Fan
Qing Xia
Shuzhen Wu
Shaoxin Ye
Li Liu
Wen Wang
Xiaoling Guo
Zhengping Liu
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Trials / Issue 1/2018
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-018-2478-x

Other articles of this Issue 1/2018

Trials 1/2018 Go to the issue

Study protocol

Effect of a home-based exercise program on functional mobility and quality of life in elderly people: protocol of a single-blind, randomized controlled trial

Study protocol

Behavioral economics-based incentives supported by mobile technology on HIV knowledge and testing frequency among Latino/a men who have sex with men and transgender women: Protocol for a randomized pilot study to test intervention feasibility and acceptability

Study protocol

Physical activity as treatment for alcohol use disorders (FitForChange): study protocol for a randomized controlled trial

Study protocol

Motivational Interviewing as a tool to enhance access to mental health treatment in adolescents with chronic medical conditions and need for psychological support (COACH-MI): study protocol for a clusterrandomised controlled trial

Study protocol

Safe Birth and Cultural Safety in southern Mexico: study protocol for a randomised controlled trial

Study protocol

Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial